tri agonist glp 1 LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Hitting the Triple G Spot:
Description
For now, we better focus on the so what?
On 19 March 2026, the FDA approved a higher-dose formulation of semaglutide, Wegovy HD, at 7.2 mg for once-weekly subcutaneous administration
2 Medications reviewed included: semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide
Liraglutide has anti-inflammatory and anti-amyloid properties in streptozotocin-induced and 5xFAD mouse models of Alzheimers disease
